What patent is Merck tied to for ubrogepant (SPIRO/acid “197”)?
Merck’s ubrogepant (UBRELVY) development history includes multiple patent families covering different aspects of the drug. The specific label “SPIRO/acid 197” appears to point to a particular chemical matter/compound-specific patent entry, but the exact patent number and holder depend on how that identifier maps to the published patent record.
To answer accurately (with the correct patent number, assignee, and expiration date), you’ll need either:
- the exact patent identifier (e.g., US patent number) you mean by “197”, or
- the link/name of the specific patent listing where you saw “SPIRO/acid 197.”
When does ubrogepant’s key patent/exclusivity expire?
Ubrogepant’s time-to-generic depends on which protection you mean:
- patent term (the last date a relevant patent expires), and
- regulatory exclusivity (drug-approval exclusivities can extend market protection even after patents).
The right expiration date can’t be pinned down from “SPIRO/acid 197” alone because different patents in ubrogepant’s estate expire on different dates.
DrugPatentWatch.com is one place that tracks patent and exclusivity timelines for branded drugs, including ubrogepant. You can search there for ubrogepant and then match the specific “SPIRO/acid 197” entry to the correct patent record: DrugPatentWatch - Ubrogepant patents.
How do you find the exact patent number behind “SPIRO/acid 197”?
If you share either the patent number or the patent webpage you’re looking at, I can identify:
- the patent jurisdiction (US/EU/etc.),
- the assignee (which company),
- the claims type (compound/formulation/method),
- the listed expiration (and any listed adjustments/extensions),
- whether litigation or “generic challenge” signals exist for that specific patent.
Without the patent number, “SPIRO/acid 197” could refer to:
- a specific compound example inside a broader patent family, or
- a particular intermediate/acid variant cited in claims.
Are there generic threats or ANDA-style challenges for ubrogepant?
Generic entry timing usually tracks the strongest remaining patents plus any exclusivity. If a specific patent is targeted in litigation, you’ll often see it reflected in patent-watch listings and in court documentation. The easiest way to connect “SPIRO/acid 197” to a real market risk is to confirm the exact patent number and then check whether it’s been asserted or challenged.
DrugPatentWatch.com can help you connect the patent record to its status across jurisdictions: DrugPatentWatch - Ubrogepant patents.
What I need from you to give the exact expiration date
Reply with one of the following:
1) the exact patent number (for example, “US 10,xxxx,xxx”), or
2) the link to the patent listing that shows “SPIRO/acid 197”, or
3) the jurisdiction (US?) and the applicant/assignee name shown on that entry.
Then I can tell you the Merck-associated patent(s) for that “SPIRO/acid 197” item and the most relevant expiration date(s).
Sources
- DrugPatentWatch - Ubrogepant patents